groups (see Results); 6-8 days later, one group of mice was left untreated, and the other groups were given 400 rads of whole body irradiation. One group of irradiated mice was not further treated, whereas other groups were inoculated intravenously with spleen cells from nonsensitized, 6-8-wk-old BALB/c females. These spleen cells were either unfractionated, or they were enriched for, or deprived of T cells as described below.
The mice were examined twice weekly for tumor growth. Two perpendicular tumor diameters were measured. Mean tumor diameters in millimeters (X ± SE) for all sites per group were calculated, with negative sites being counted as 0. Statistical significance was estimated by Student's t test. All mice were ear-tagged. The treatment of the mice was unknown to the person scoring the animals.
Mice and Tumors. BALB/c mice were bred by brother/sister mating, and were regularly checked for their ability to accept intrastrain skin grafts. 6-8-wk-old females were used.
Two methylcholanthrene-induced sarcomas, 1315 and 1425 (10) , were maintained by serial transplantation for 10-15 passages before use. Both possess strong individually unique TSTA, weak common tumor-associated antigens (10) , and murine leukemia virus-associated antigens (11) .
Tumor cell suspensions were prepared from fragments of healthy tissue by trypsinization (0.025% trypsin and 5 mM EDTA for 10 min), and they were washed in Waymouth's medium (Grand Island Biological Co., Grand Island, N. Y.). The mice were inoculated subcutaneously with 10 e viable tumor cells into each flank.
Irradiation Procedures. Mice were given a sublethal dose (400 rads) of whole body irradiation from two opposing cobalt-60 sources.
Preparation of T-Cell-Enricked Spleen Cell Suspensions. Nylon wool columns to which non-T cells would bind preferentially were utilized according to Julius et al. (12) . After column passage, 88-94% of the nonadherent cells were killed by a mouse anti-Thy-1.2 serum and complement, compared to 28-39% of the unfractionated spleen cells.
Preparation and Testing of a Goat Anti-T-Cell Serum.
A goat was immunized three times subcutaneously with rat brain in complete Freund's adjuvant (Difco Laboratories, Detroit, Mich.) to obtain antibodies cross-rcacting to mouse T lymphocytes (13) . The antiserum, which was heat-inactivated (56°C, 30 min) and exhaustively absorbed with BALB/c bone marrow cells, was tested on various BALB/c lymphoid cells for complement-dependent cytotoxicity, using a nlCr release assay. After the last absorption, bone marrow cells were not affected by the serum plus complement at all, whereas 90% of thymus cells and 25-35% of spleen cells were killed at a serum dilution of 1:50. Spleen cells incubated with 1:50 diluted antiserum and complement retained full ability to synthesize DNA upon exposure to lipopolysaccharide, while their ability to proliferate upon exposure to phytohemagglutinin was lost. This antiserum abolished the in vitro cytotoxic activity of aUoimmune lymphocytes (14) , as well as the in vivo reactivity of tumor-immune lymphocytes in (Winn) neutralization assays (unpublished observations).
To prepare T-deprived spleen cells for adoptive transfer, 2.5 × 107 cells/ml were suspended in Waymouth's medium, and an equal volume of 1:7 diluted goat anti-T serum was added. The mixture was incubated for 2 h at 4°C, after which pretested (nontoxic) rabbit complement (from 10-wk-old San Juan rabbits) was added to a final dilution of 1:20 and the mixtures were incubated at 37°C for 1 h. The cells were then washed twice, diluted in Waymouth's medium, and counted.
Results
Two preliminary tests showed that whole body irradiation of mice carrying sarcoma 1315 decreased tumor growth, provided that the irradiation was done 6-8 days after tumor transplantation (when the tumor just started appearing); no such effect of radiation was seen when it was given 10 or more days after transplantation. We decided, therefore, to start our treatments 6-8 days after tumor transplantation.
Three experiments were performed. In the first, 10 s cells from sarcoma 1315 were transplanted subcutaneously into each flank of syngeneic BALB/c females. 8 days later, the mice were randomized into three groups of 10 mice each (Table I) * On day 1 the mice were inoculated subcutaneously in each flank with 10 e sarcoma 1315 cells. Mice in groups B and C were irradiated on day 8, and mice in group C were also injected intravenously with 5 × l0 s syngeneic spleen cells 2 h later. :~ In all 7 cas~, small tumors were observed to regres completely. § The statistical significance of the differenceg between groups in mean tumor diameter was determined by Student's t tests; significance in frequenc~ of tumor regression was determined from Fischer Table. NS, not significant; X, mean.
A was untreated, group B was given 400 rads of whole body irradiation, and group C was given 400 rads of whole body irradiation, followed in 2 h by the intravenous injection of 5 × l0 s viable lymphoid ceils from the spleens of normal BALB/c females. Tumor growth was significantly inhibited in the irradiated mice that received no spleen cells (group B). After an initial, weak inhibition seen in the irradiated group that received spleen cells (group C), tumor growth in this group was essentially the same as in the untreated mice (group A). Most remarkably, complete regression of tumors that had first grown to 2-4-mm diameters, was seen in 7 of 20 sites in group B; three mice had regression of their tumors on both sides, and remained tumor-free more than 3 mo later, by which time all the 20 control mice (groups A and C) and the remaining 7 mice in group B had died from tumor. The lymphoid cells facilitating tumor growth upon adoptive transfer to irradiated mice were T cells. As shown in Table II , the growth of sarcoma 1315 was significantly inhibited by whole body irradiation (group B), and four complete regressions were observed. The therapeutic effect of the irradiation was counteracted by the intravenous injection of 2 × 10 7 unfractionated spleen cells (group C), thus confirming our observations in Table I . The tumors of the irradiated mice passively receiving T-cellenriched spleen cells (group D) grew like the tumors in the untreated controls (group A), whereas the tumors of the irradiated mice receiving 2 × 10 7 T-depleted spleen cells (group E) grew much more slowly, and six of these regressed completely (and permanently).
In a third experiment, we also showed a therapeutic effect of irradiation on another sarcoma, 1425, which had been independently induced by methylcholanthrene. However, the effect of irradiation was less pronounced than with sarcoma 1315. The 1425 tumors in the irradiated mice receiving T-deprived spleen cells were significantly smaller after 15 (P < 0.01) and 20 days (P < 0.001) of growth than the tumors in the irradiated mice receiving T-enriched spleen cells, but this difference disappeared completely by 29 days of tumor growth.
Discussion
We have presented evidence that tumor growth can be inhibited significantly when * The mice were inoculated on day I subcutaneously in each flank with 10 b cells fi'om sarcoma 1315 (pIoviding 2 tumor sites per mottsc) 400 rads of whole body irradiation were given on day 6 or 8 after tumor transplantation. Spleen cells were int~:ulated intravenously 2 h aft(') irradiation; procedures for obtaining T-enriched and T-deprived spleen cell suspensions are described m Material~ and Methods :~ In all 10 cases, small tumors werv observed to regress completely § See footnote to Table I mice carrying small, subcutaneously transplanted tumors are given 400 rads of whole body irradiation. Most importantly, on several occasions complete tumor regressions were seen in irradiated mice carrying 1315 sarcomas. The cells affected by the radiation treatment were most likely lymphoid cells rather than tumor cells, since intravenous injection of spleen cells from nonsensitized, syngeneic mice abolished the radiation effect. The responsible spleen cells were T lymphocytes. These observations support the hypothesis that a population of suppressor T cells exists in tumor-bearing animals where it plays an important role in facilitating the growth of immunogenic tumors. It also suggests that the suppressor cells, at least in the early phase of tumor growth (between 6 and 8 days), are recruited from a cell population which is sensitive to irradiation. At a later stage of tumor growth (10 days or later), a similar effect of whole body irradiation was not observed. This loss of the therapeutic effect of irradiation may be related to the eclipse phenomenon (15) , and/or to the presence of appreciable amounts of circulating tumor antigens and other blocking factors (16) at that time, including those already formed by suppressor T cells (17) . These phenomena are both related to tumor load (18) . The development of resistant to irradiation could also be due to the presence of already activated suppressor cells which may have become less radiosensitive than the cell population from which they were derived (19) . We are presently conducting experiments to explore these possibilities.
The therapeutic effect of irradiation was most dramatic against the 1315 sarcoma. Although this tumor, which we have studied extensively, does not regress normally, we observed about 30% permanent regressions as a result of irradiation in this study. Irradiation significantly retarded the growth of 1425 sarcomas, but this effect disappeared completely after 4 wk of tumor growth. The difference between these two tumors may relate to a difference in their immunogenicity, since 1315 is the more immunogenic of the two in standard transplantation tests (10) . Recently, we have obtained results similar to those for 1425 with another sarcoma, 1460, which is also less immunogenic than 1315. These observations emphasize the fact that each tumor is unique, and that different modalities may be required to achieve the same therapeutic effect.
We believe, nevertheless, that the approach described here, as well as the use of drugs such as cyclophosphamide instead of irradiation to preferentially interfere with suppressor cell activity while leaving the effector cell activities intact (20) , can have general applicability to treating tumors of the mouse. An approach aimed at interference with suppressor cell activity may also have value as an adjunct to human cancer therapy.
We are anxious to point out, however, that we have not excluded that the radiation effect is due to the elimination of radiosensitive cells responsible for immunostimulation (21) , and perhaps contributing to a stromal reaction contributing to the size of tumor nodules. This explanation is less likely, however, since our tumors grow well in nonimmunized BALB/c mice receiving 400 rads, and since permanent regression was seen in 17 of 50 tumor sites. Summary BALB/c mice were inoculated subcutaneously with 106 cells from either of two syngeneic sarcomas 1315 and 1425. 6-8 days later, the mice were randomized into groups which were left untreated or given 400 rads of whole body irradiation. Irradiation significantly retarded the growth of both sarcomas, and complete regressions were seen of ~ 30% of the small, established 1315 tumors. The anti-tumor effect of irradiation was abolished if the irradiated mice were inoculated with a T-cellenriched (but not with a T-cell-deprived) suspension of syngeneic spleen cells, suggesting that the irradiation inhibited tumor growth by affecting a radiosensitive population of host suppressor T cells.
